Recent News

ESMO Asia 2020: SOLO1 Update on Olaparib Maintenance for BRCA-Mutated Ovarian Cancer

Serous Ovarian Cancer: Paclitaxel Dosing Comparison From VELIA Trial

Chemoimmunotherapy Triplet Under Study in Recurrent Ovarian Cancer

Oral Cyclophosphamide Plus Bevacizumab in Recurrent Ovarian Cancer

Resensitization of Ovarian Cancer to Carboplatin Using Oncolytic Vaccine

Fixed Versus Individual Starting Dose of Niraparib in Advanced Ovarian Cancer

Novel TIE2 Kinase Inhibitor Under Study in Platinum-Resistant Ovarian Cancer

Use of Bevacizumab Beyond Disease Progression in Platinum-Resistant Ovarian Cancer

Maintenance Olaparib in Advanced Ovarian Cancer: SOLO-1 Long-Term Survival Update

Immunochemotherapy Primed With Oncolytic Vaccinia Virus in Platinum-Resistant Ovarian Cancer

ESMO 2020: Impact of Rising CA-125 Levels in Treating Platinum-Sensitive Recurrent Ovarian Cancer

Ongoing Study of Afuresertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer

ESMO 2020: Maintenance Niraparib in Older Patients With Advanced Ovarian Cancer

ESMO 2020: Overall Survival With Weekly Dose-Dense Chemotherapy for Ovarian Cancer

IGCS 2020: Lenvatinib Plus Pembrolizumab in Ovarian Cancer

ESMO 2020: Novel PARP Inhibitor Under Study in Advanced Ovarian Cancer

IGCS 2020: Addition of Veliparib to Carboplatin Paclitaxel in Newly Diagnosed Ovarian Cancer

ESMO 2020: Olaparib Plus Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer

IGCS 2020: Paclitaxel Plus Tumor-Treating Fields for Platinum-Resistant Ovarian Cancer

Does Shifting to Ultra-Radical Surgery Improve Outcomes in Advanced Epithelial Ovarian Cancer?

IGCS 2020: Maintenance Immunotherapy for Stage III or IV Ovarian Cancer

IGCS 2020: Biomarker Analyses From JAVELIN Ovarian 100 Trial

Incomplete Pregnancy and Risk of Invasive Ovarian Cancer

SGO Practice Statement: PARP Inhibitor Maintenance Therapy for Ovarian Cancer

Two-Step Surgical Approach to Ovarian Cancer Prevention: Survey of Premenopausal Women

Can a Prognostic Gene-Expression Signature Predict Survival in Ovarian Cancer?

Insomnia Impacts Many Women With Ovarian Cancer

Hormone Therapy Prior to Ovarian Cancer Diagnosis: Impact on Survival?

ASCO Guideline for Using PARP Inhibitors to Manage Ovarian Cancer

FDA Brief: Antibody XMT-1536 Receives Fast Track Designation for Ovarian Cancer

Novel Reversible LSD1 Inhibitor in Mutated Ovarian Cancer

New Tool May Aid in Identifying Subtypes of Ovarian Cancer

Targeted Therapy With Crizotinib for ROS1-Mutant Ovarian Cancer: Case Study

Novel First-in-Class Agent Shows Activity in High-Grade Serous Ovarian Cancer

NCI Funds Projects to Study Racial Disparities Among Women With Ovarian Cancer

Noninvasive Early Molecular Diagnosis of High-Grade Serous Epithelial Ovarian Cancer

Epithelial Ovarian Cancer: Risk Factors May Explain Racial Differences in Incidence

Novel ATR Inhibitor Under Study in Platinum-Resistant High-Grade Serous Ovarian Cancer

Ovarian Cancer and COVID-19: Challenges in Surgical Treatment

AACR II: Antibody-Drug Conjugate Targets CLDN6/9 in Epithelial Ovarian Cancer

AACR II: Synergistic Effects of Crizotinib and Olaparib in Ovarian Cancer

Study Assesses Risks Associated With Minimally Invasive Surgery for Early-Stage Ovarian Cancer

COVID-19 and Gynecologic Cancer: SGO Expert Panel Offers Clinical Considerations

BRCA-Mutated Ovarian Cancer and COVID-19: A Potential Alternative to Surgery

HIPEC Plus Secondary Cytoreductive Surgery for Resistant Ovarian Cancer

AACR II: Do Ovarian Cancer Survivors Have an Increased Risk for Type 2 Diabetes?

ASCO20: Is Quality of Life Shaped by Sleep Schedules in Ovarian Cancer Survivors?

AACR II: Lipophilic Statins and Ovarian Cancer Mortality

ASCO20: Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer

Hospital Case Load May Affect Survival in Ovarian Cancer

ASCO20: Autologous Tumor Immunotherapy Plus Atezolizumab in Recurrent Ovarian Cancer

ASCO20: Antibody-Drug Conjugate Plus Bevacizumab in Platinum-Agnostic Ovarian Cancer

ASCO20: Does Secondary Cytoreductive Surgery Offer Survival Benefit in Recurrent Ovarian Cancer?

ASCO20: Comparing Cediranib Regimens With Standard Chemotherapy in Recurrent Ovarian Cancer